Delivery systems for Leishmania vaccine development

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Review of Vaccines

• Publication date

  2016-03-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1586/14760584.2016.1157478PMID 26905526
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvants and delivery systems for antifungal vaccines: current state and future developments.

  2015cited by this paper
• Vaccination Produces CD4 T Cells with a Novel CD154–CD40-Dependent Cytolytic Mechanism

  2015cited by this paper
• From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE

  2015cited by this paper
• Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities.

  2015cited by this paper
• Efficacy of Recombinant Canine Distemper Virus Expressing Leishmania Antigen against Leishmania Challenge in Dogs

  2015cited by this paper
• Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model.

  2015cited by this paper
• Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis

  2015cited by this paper
• Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.

  2015cited by this paper
• Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis

  2015cited by this paper
• VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.

  2015cited by this paper
• Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis.

  2015cited by this paper
• Humoral immune responses in DNA vaccine formulated with poly (methyl methacrylate) against Leishmania major

  2014cited by this paper
• A Listeria monocytogenes-Based Vaccine That Secretes Sand Fly Salivary Protein LJM11 Confers Long-Term Protection against Vector-Transmitted Leishmania major

  2014cited by this paper
• Vaccines to prevent leishmaniasis

  2014cited by this paper
• A Dual Drug Sensitive L. major Induces Protection without Lesion in C57BL/6 Mice

  2014cited by this paper
• The role of surface charge of ISCOMATRIX nanoparticles on the type of immune response generated against Leishmaniasis in BALB/c mice

  2014cited by this paper
• Combining Cationic Liposomal Delivery with MPL-TDM for Cysteine Protease Cocktail Vaccination against Leishmania donovani : Evidence for Antigen Synergy and Protection

  2014cited by this paper
• Enhanced Protective Efficacy of Nonpathogenic Recombinant Leishmania tarentolae Expressing Cysteine Proteinases Combined with a Sand Fly Salivary Antigen

  2014cited by this paper
• Characterization of Cross-Protection by Genetically Modified Live-Attenuated Leishmania donovani Parasites against Leishmania mexicana

  2014cited by this paper
• Liposomes as vaccine delivery systems: a review of the recent advances

  2014cited by this paper
• Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.

  2013cited by this paper
• Cationic solid–lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice

  2013cited by this paper
• Applications of nanotechnology for immunology

  2013cited by this paper
• Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).

  2013cited by this paper
• Development of Novel Prime-Boost Strategies Based on a Tri-Gene Fusion Recombinant L. tarentolae Vaccine against Experimental Murine Visceral Leishmaniasis

  2013cited by this paper
• Salmonella as a vaccine delivery vehicle

  2013cited by this paper
• Liposome: classification, preparation, and applications

  2013cited by this paper
• Viral vectors: a look back and ahead on gene transfer technology.

  2013cited by this paper
• Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice

  2013cited by this paper
• Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.

  2012cited by this paper
• Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11

  2012cited by this paper
• The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen.

  2012cited by this paper
• Evaluation of Recombinant Leishmania Polyprotein Plus Glucopyranosyl Lipid A Stable Emulsion Vaccines against Sand Fly-Transmitted Leishmania major in C57BL/6 Mice

  2012cited by this paper
• Preparation and evaluation of niosomes containing autoclaved Leishmania major: a preliminary study

  2012cited by this paper
• Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies.

  2012cited by this paper
• Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.

  2012cited by this paper
• The role of liposome-protamine-DNA nanoparticles containing CpG oligodeoxynucleotides in the course of infection induced by Leishmania major in BALB/c mice.

  2012cited by this paper
• Immunization against Leishmania major Infection Using LACK- and IL-12-Expressing Lactococcus lactis Induces Delay in Footpad Swelling

  2012cited by this paper
• Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis

  2012cited by this paper
• Induction of Protective CD4+ T Cell-Mediated Immunity by a Leishmania Peptide Delivered in Recombinant Influenza Viruses

  2012cited by this paper
• Proteinases as virulence factors in Leishmania spp. infection in mammals

  2012cited by this paper
• Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis.

  2011cited by this paper
• Single Dose Novel Salmonella Vaccine Enhances Resistance against Visceralizing L. major and L. donovani Infection in Susceptible BALB/c Mice

  2011cited by this paper
• Non-ionic surfactant vesicles mediated transcutaneous immunization against hepatitis B.

  2011cited by this paper
• Potentiating Effects of MPL on DSPC Bearing Cationic Liposomes Promote Recombinant GP63 Vaccine Efficacy: High Immunogenicity and Protection

  2011cited by this paper
• Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation

  2011cited by this paper
• Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection.

  2011cited by this paper
• C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice

  2011cited by this paper
• Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN

  2011cited by this paper
• Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice.

  2011cited by this paper
• Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice

  2011cited by this paper
• Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations.

  2010cited by this paper
• Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.

  2010cited by this paper
• Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.

  2010cited by this paper
• Enhancement of IL-10 bioactivity using an IL-10 peptide-based vaccine exacerbates Leishmania major infection and improves airway inflammation in mice.

  2010cited by this paper
• Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.

  2010cited by this paper
• The Role of Liposomal CpG ODN on the Course of L. major Infection in BALB/C Mice

  2010cited by this paper
• Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition.

  2009cited by this paper
• Vaccination Route That Induces Transforming Growth Factor β Production Fails To Elicit Protective Immunity against Leishmania donovani Infection

  2009cited by this paper
• Identification of Novel Leishmania donovani Antigens that Help Define Correlates of Vaccine-Mediated Protection in Visceral Leishmaniasis

  2009cited by this paper
• The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).

  2009cited by this paper
• Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.

  2009cited by this paper
• Intracellular Replication-Deficient Leishmania donovani Induces Long Lasting Protective Immunity against Visceral Leishmaniasis

  2009cited by this paper
• PMMA particle-mediated DNA vaccine for cervical cancer.

  2009cited by this paper
• Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis

  2009cited by this paper
• gp63 in Stable Cationic Liposomes Confers Sustained Vaccine Immunity to Susceptible BALB/c Mice Infected with Leishmania donovani

  2008cited by this paper
• Coencapsulation of CpG Oligodeoxynucleotides with Recombinant Leishmania major Stress-Inducible Protein 1 in Liposome Enhances Immune Response and Protection against Leishmaniasis in Immunized BALB/c Mice

  2008cited by this paper
• Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.

  2007cited by this paper
• Alginate Microsphere as a Delivery System and Adjuvant for Autoclaved Leishmania major and Quillaja Saponin: Preparation and Characterization

  2007cited by this paper
• The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.

  2007cited by this paper
• Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice.

  2007cited by this paper
• Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.

  2007cited by this paper
• Intraperitoneal immunization with oligomannose‐coated liposome‐entrapped soluble leishmanial antigen induces antigen‐specific T‐helper type immune response in BALB/c mice through uptake by peritoneal macrophages

  2007cited by this paper
• Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.

  2006cited by this paper
• Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.

  2006influential reference
• Enhanced and prolonged cross‐presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles

  2006cited by this paper
• Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate.

  2006cited by this paper
• Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice.

  2006cited by this paper
• Photodynamic therapy as a new treatment of cutaneous leishmaniasis.

  2006cited by this paper
• Live Nonpathogenic Parasitic Vector as a Candidate Vaccine against Visceral Leishmaniasis

  2005cited by this paper
• Evaluation of immune response against leishmaniasis in resistance C57 BL-6 mice immunized with liposomes containing autoclaved Leishmania major with BCG

  2005influential reference
• INFLUENCE OF PHOSPHOLIPID COMPOSITION ON THE ADJUVANTICITY AND PROTECTIVE EFFICACY OF LIPOSOME-ENCAPSULATED LEISHMANIA DONOVANI ANTIGENS

  2005cited by this paper
• Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis.

  2005cited by this paper
• Stimulation of Triglyceride-Rich Lipoprotein Secretion by Polysorbate 80: In Vitro and in Vivo Correlation Using Caco-2 Cells and a Cannulated Rat Intestinal Lymphatic Model

  2004cited by this paper
• A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.

  2004cited by this paper
• Vaccines that facilitate antigen entry into dendritic cells

  2004cited by this paper
• Protection against Leishmania major infection by oligomannose-coated liposomes.

  2003cited by this paper
• Characterization of Leishmania donovani Antigens Encapsulated in Liposomes That Induce Protective Immunity in BALB/c Mice

  2002cited by this paper
• Solid lipid nanoparticles: production, characterization and applications.

  2001cited by this paper
• Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil.

  2000cited by this paper
• INDUCTION OF PARTIAL PROTECTION AGAINST LEISHMANIA DONOVANI BY PROMASTIGOTE ANTIGENS IN NEGATIVELY CHARGED LIPOSOMES

  2000cited by this paper
• BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice.

  2000cited by this paper
• Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.

  2000cited by this paper
• Vaccination of C57BL/10 mice against cutaneous leishmaniasis. Use of purified gp63 encapsulated into niosomes surfactants vesicles: a novel approach.

  1999cited by this paper
• Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis.

  1998cited by this paper
• ISCOMs vaccine against experimental leishmaniasis.

  1998influential reference
• Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection.

  1998cited by this paper
• Lipopolysaccharide-induced interleukin 8 production by human whole blood is enhanced by epinephrine and inhibited by hydrocortisone

  1997cited by this paper
• Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice.

  1995cited by this paper
• Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63.

  1993cited by this paper

• Designing of a new multi-epitope vaccine against Leishmania major using Leish-F1 epitopes: An In-silico study

  2024cites this paper
• The Novel Treatments Based on Tissue Engineering, Cell Therapy and Nanotechnology for Cutaneous Leishmaniasis.

  2023cites this paper
• Investigation of Leish-111f Epitopes to Design a New Multi-epitope Vaccine Against Leishmania Major Using Immunoinformatics Approaches

  2021cites this paper
• Development of a successful vaccine for leishmaniasis: possibilities and challenges

  2021cites this paper
• Nanotechnology-aided Diagnosis, Treatment and Prevention of Leishmaniasis.

  2021cites this paper
• Development of nano-carriers for Leishmania vaccine delivery

  2020influential citation
• Vaccine Design, Nanoparticle Vaccines and Biomaterial Applications

  2020cites this paper
• Chitosan-based particulate systems for drug and vaccine delivery in the treatment and prevention of neglected tropical diseases

  2020cites this paper
• Chitosan-based particulate systems for drug and vaccine delivery in the treatment and prevention of neglected tropical diseases

  2020cites this paper
• Novel multi-epitope protein containing conserved epitopes from different Leishmania species as potential vaccine candidate: Integrated immunoinformatics and molecular dynamics approach

  2019cites this paper
• Recent progress in drug targets and inhibitors towards combating leishmaniasis.

  2018cites this paper
• Vaccines for Human Leishmaniasis: Where Do We Stand and What Is Still Missing?

  2018cites this paper
• A Leishmania hypothetical protein‐containing liposome‐based formulation is highly immunogenic and induces protection against visceral leishmaniasis

  2018cites this paper
• Leishmaniasis in humans: drug or vaccine therapy?

  2017cites this paper
• Innovative Approaches to Improve Anti-Infective Vaccine Efficacy.

  2017cites this paper
• Identification of BALB/c Immune Markers Correlated with a Partial Protection to Leishmania infantum after Vaccination with a Rationally Designed Multi-epitope Cysteine Protease A Peptide-Based Nanovaccine

  2017cites this paper
• Last Decade Developments on Leishmania Vaccines with Emphasis on Nanovaccines

  2017cites this paper
• Lipid based delivery and immuno-stimulatory systems: Master tools to combat leishmaniasis.

  2016cites this paper